Michael Tachezy

Dr. Michael Tachezy

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MTMichael Tachezy
Michael Tachezy
FGFlorian Gebauer
Florian Gebauer
CPCordula Petersen
Cordula Petersen
DADirk Arnold
Dirk Arnold
MTMartin Trepel
Martin Trepel
EYEmre Yekebas
Emre Yekebas
Median OS after surgery in curative intent for non-metastasized pancreas cancer ranges under study conditions from 17.9 months to 23.6 months. Tumor recurrence occurs locally, at distant sites (liver, peritoneum, lungs), or both. Observational and autopsy series report local recurrence rates of up to 87% even after potentially “curative” R0 resection. To achieve better local control, neoadjuvant CRT has been suggested for preoperative tumour downsizing, to elevate the likelihood of curative, margin-negative R0 resection and to increase the OS rate. However, controlled, randomized trials addressing the impact of neoadjuvant CRT survival do not exist.

5 February 2014 in Stem Cells
Verified
Journal Article
Open access
PDF file
MTMichael Tachezy
Michael Tachezy
HZHilke Zander
Hilke Zander
Gerrit Wolters-EisfeldGerrit Wolters-Eisfeld
Gerrit Wolters-Eisfeld
JMJulia Müller
Julia Müller
DWDaniel Wicklein
Daniel Wicklein
MBMaximilian Bockhorn
Maximilian Bockhorn
Recently, the activated leukocyte cell adhesion molecule (CD166) was identified as an “inert” cancer stem cell (CSC) marker for non‐small cell lung cancer (NSCLC). Few data exist regarding the clinical relevance of CD166 expression in NSCLC. We evaluated the expression of CD166 using immunohistochemistry in a large cohort of NSCLC patients (n = 1,910) on a tissue microarray basis. Expression was inversely associated with tumor size and lymph node status. Grading slightly failed to be significantly inversely associated, and survival analysis revealed no significant survival benefit of CD166‐positive patients. Due to the results of this study, the theory of CD166 as a CSC marker for NSCLC must be questioned. The association of CD166 with smaller tumors and no nodal metastases does not make it a typical CSC marker. Further studies are required to investigate the functional role of CD166 in NSCLC. Stem Cells 2014;32:1429–1436

1 January 2013 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
MTMichael Tachezy
Michael Tachezy
HZHilke Zander
Hilke Zander
FGFlorian Gebauer
Florian Gebauer
KLKatharina von Loga
Katharina von Loga
KPKlaus Pantel
Klaus Pantel
MBMaximilian Bockhorn
Maximilian Bockhorn
The chemokine CXCL12 and its receptor CXCR4 play a major role in tumor invasion, proliferation and metastasis in different malignant diseases, including esophageal carcinoma, amongst others. CXCR7 was recently identified as a novel alternate receptor for CXCL12. The aim of this study was to evaluate the prognostic impact of expression of chemokine receptor CXCR7 in patients with esophageal carcinoma (EC).

22 May 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HZHilke Zander
Hilke Zander
TRTamina Rawnaq
Tamina Rawnaq
MWMax von Wedemeyer
Max von Wedemeyer
MTMichael Tachezy
Michael Tachezy
MKMiriam Kunkel
Miriam Kunkel
JKJussuf Kaifi
Jussuf Kaifi
L1 cell adhesion molecule (CD171) is expressed in many malignant tumors and its expression correlates with unfavourable outcome. It thus represents a target for tumor diagnosis and therapy. An earlier study conducted by our group identified L1 expression levels in primary gastrointestinal stromal tumors (GIST) as a prognostic marker. The aim of the current study was to compare L1 serum levels of GIST patients with those of healthy controls and to determine whether levels of soluble L1 in sera could serve as a prognostic marker.

7 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AGAnastasios D. Giannou
Anastasios D. Giannou
JLJöran Lücke
Jöran Lücke
DKDörte Kleinschmidt
Dörte Kleinschmidt
ASAhmad Mustafa Shiri
Ahmad Mustafa Shiri
BSBabett Steglich
Babett Steglich
Samuel HuberSamuel Huber
Samuel Huber
Hepatocellular carcinoma (HCC) ranks among the five most common cancer entities worldwide and leads to hundred-thousands of deaths every year. Despite some groundbreaking therapeutical revelations during the last years, the overall prognosis remains poor. Although the immune system fights malignant transformations with a robust anti-tumor response, certain immune mediators have also been shown to promote cancer development. For example, interleukin (IL)-22 has been associated with HCC progression and worsened prognosis in multiple studies. However, the underlying mechanisms of the pathological role of IL-22-signaling as well as the role of its natural antagonist IL-22 binding protein (IL-22BP) in HCC remain elusive. Here, we corroborate the pathogenic role of IL-22 in HCC by taking advantage of two mouse models. Moreover, we observed a protective role of IL-22BP during liver carcinogenesis. While IL-22 was mainly produced by CD4+ T cells in HCC, IL-22BP was abundantly expressed by neutrophils during liver carcinogenesis. Hepatocytes could be identified as a major target of this pathological IL-22-signaling. Moreover, abrogation of IL-22 signaling in hepatocytes in IL22ra1flox/flox × AlbCre+ mice reduced STEAP4 expression-a known oncogene-in HCC in vivo. Likewise, STEAP4 expression correlated with IL22 levels in human HCC samples, but not in healthy liver specimens. In conclusion, these data encourage the development of therapeutical approaches that target the IL-22–IL-22BP axis in HCC.

8 March 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
FGFlorian Gebauer
Florian Gebauer
SGSuyin Gelis
Suyin Gelis
HZHilke Zander
Hilke Zander
KMKarl-Frederick Meyer
Karl-Frederick Meyer
Gerrit Wolters-EisfeldGerrit Wolters-Eisfeld
Gerrit Wolters-Eisfeld
MTMichael Tachezy
Michael Tachezy
Tenascin-C serum levels and its prognostic power in non-small cell lung cancer